137 related articles for article (PubMed ID: 26829101)
1. Reformulating cyclosporine A (CsA): More than just a life cycle management strategy.
Guada M; Beloqui A; Kumar MN; Préat V; Dios-Viéitez Mdel C; Blanco-Prieto MJ
J Control Release; 2016 Mar; 225():269-82. PubMed ID: 26829101
[TBL] [Abstract][Full Text] [Related]
2. Modern approaches to the ocular delivery of cyclosporine A.
Agarwal P; Rupenthal ID
Drug Discov Today; 2016 Jun; 21(6):977-88. PubMed ID: 27080149
[TBL] [Abstract][Full Text] [Related]
3. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.
Guada M; Sebastián V; Irusta S; Feijoó E; Dios-Viéitez Mdel C; Blanco-Prieto MJ
Int J Nanomedicine; 2015; 10():6541-53. PubMed ID: 26527872
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS
Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447
[TBL] [Abstract][Full Text] [Related]
5. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study.
Mondon K; Zeisser-Labouèbe M; Gurny R; Möller M
Eur J Pharm Biopharm; 2011 Jan; 77(1):56-65. PubMed ID: 20888909
[TBL] [Abstract][Full Text] [Related]
6. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs.
Biagiotti S; Rossi L; Bianchi M; Giacomini E; Pierigè F; Serafini G; Conaldi PG; Magnani M
J Control Release; 2011 Sep; 154(3):306-13. PubMed ID: 21640771
[TBL] [Abstract][Full Text] [Related]
7. Circumventing the blood-brain barrier: Local delivery of cyclosporin A stimulates stem cells in stroke-injured rat brain.
Tuladhar A; Morshead CM; Shoichet MS
J Control Release; 2015 Oct; 215():1-11. PubMed ID: 26226344
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a cyclosporine solid dispersion for inhalation.
Zijlstra GS; Rijkeboer M; Jan van Drooge D; Sutter M; Jiskoot W; van de Weert M; Hinrichs WL; Frijlink HW
AAPS J; 2007 Jun; 9(2):E190-9. PubMed ID: 17614361
[TBL] [Abstract][Full Text] [Related]
9. A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.
Guo H; Lee C; Shah M; Janga SR; Edman MC; Klinngam W; Hamm-Alvarez SF; MacKay JA
J Control Release; 2018 Dec; 292():183-195. PubMed ID: 30359668
[TBL] [Abstract][Full Text] [Related]
10. Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability.
Woo JS; Piao MG; Li DX; Ryu DS; Choi JY; Kim JA; Kim JH; Jin SG; Kim DD; Lyoo WS; Yong CS; Choi HG
Int J Pharm; 2007 Dec; 345(1-2):134-41. PubMed ID: 17950545
[TBL] [Abstract][Full Text] [Related]
11. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
Ray JE; Keogh AM; McLachlan AJ
J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
[TBL] [Abstract][Full Text] [Related]
12. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
13. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.
Hirunpanich V; Sato H
Eur J Pharm Biopharm; 2009 Oct; 73(2):247-52. PubMed ID: 19560537
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A: a review of current oral and intravenous delivery systems.
Beauchesne PR; Chung NS; Wasan KM
Drug Dev Ind Pharm; 2007 Mar; 33(3):211-20. PubMed ID: 17454054
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
16. Combination of N-(3'4'-dimethoxycinnamoyl) anthranilic acid with cyclosporin A treatment preserves immunosuppressive effect and reduces the side effect of cyclosporin A in rat.
Yong-Gang X; Ming-Zhe W; Jin-Yan Z; Zhi-Hai P; Jun-Ming X
Eur J Pharmacol; 2014 Apr; 728():16-23. PubMed ID: 24530417
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling of gel nanoparticles with cyclosporine A for oral drug delivery.
Tokarský J; Andrýsek T; Capková P
Int J Pharm; 2011 May; 410(1-2):196-205. PubMed ID: 21421033
[TBL] [Abstract][Full Text] [Related]
18. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibitory effect of cyclosporin A and vitamin D derivatives on T-lymphocyte proliferation in active ulcerative colitis.
Stio M; Treves C; Celli A; Tarantino O; d'Albasio G; Bonanomi AG
Am J Gastroenterol; 2002 Mar; 97(3):679-89. PubMed ID: 11922564
[TBL] [Abstract][Full Text] [Related]
20. Self-assembling colloidal system for the ocular administration of cyclosporine A.
Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
